Results 71 to 80 of about 8,117 (271)
BackgroundEosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis characterized by asthma, systemic manifestations, and blood and tissue eosinophilia.ObjectiveTo assess the effectiveness and safety of mepolizumab (anti-IL-5) and ...
Santi Nolasco+20 more
doaj +1 more source
We Have to Learn to Do Without Knowing Enough: Anti-Eosinophilic Treatments for Severe Asthma [PDF]
Interleukin.5 (IL.5) is the main eosinophilic cytokine that promotes the differentiation, survival, and activation of eosinophils, which are the key inflammatory cells in severe eosinophilic asthma .Thus, it is no surprise that ...
4,+3 more
core +1 more source
Background: Recently, mepolizumab and benralizumab have been approved for the treatment of severe eosinophilic asthma. Objective: Thus, the main objective of the current study was to find out the exact efficacy and safety profile of mepolizumab and ...
Noor Alam, S. Latha, Anoop Kumar
doaj
Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma [PDF]
Peer reviewedPublisher ...
Walsh, Garry Michael
core +2 more sources
Several randomized controlled trials (RCTs) have shown that benralizumab is characterized by a good profile of efficacy and safety, thereby being potentially able to elicit clinical remission on‐treatment of severe eosinophilic asthma (SEA).
C. Pelaia+27 more
semanticscholar +1 more source
Reductions in eosinophil biomarkers by benralizumab in patients with asthma [PDF]
Eosinophilic inflammation is frequently associated with increased asthma severity. Benralizumab is a humanized, afucosylated, anti-interleukin-5Rα monoclonal antibody that selectively depletes eosinophils and basophils through enhanced antibody-dependent cell-mediated cytotoxicity.To study effects of benralizumab on eosinophil counts and activity ...
Koustubh Ranade+3 more
openaire +3 more sources
Anaphylaxis to three humanized antibodies for severe asthma: a case study
Background Omalizumab, mepolizumab, benralizumab, and dupilumab are the currently available biologics used to treat asthma in Japan. Anaphylaxis following treatment with mepolizumab or benralizumab is considered rare. Case presentation We report the case
Koichi Jingo+9 more
doaj +1 more source
Severe Toxic Epidermal Necrolysis and Drug Reaction with Eosinophilia and Systemic Symptoms Overlap Syndrome Treated with Benralizumab: A Case Report [PDF]
TEN/DRESS overlap syndrome can be difficult to diagnose, especially if it is masked by comorbidities in critically ill patients in intensive care units. The existing therapy for the two conditions is also a major challenge for the treating team.
Bader, Patrick R+4 more
core +1 more source
Eosinophils play an important pathogenetic role in the development of eosinophilic granulomatosis with polyangiitis (EGPA). EGPA has long been treated with systemic corticosteroids and immunosuppressive agents.
Osamu Matsuno, Seijiro Minamoto
doaj
Efficacy and safety of benralizumab in elderly patients with severe eosinophilic asthma
Background Biologics are the important drugs for severe asthma, but clinical trials included few elderly patients. Data on the safety and efficacy of benralizumab in elderly asthma patients are limited.Methods This clinical study was a multicentre ...
Kohei Somekawa+19 more
doaj +1 more source